

NOTICE TO THE BAR

MULTICOUNTY LITIGATION – CONCLUSION OF BENICAR OLMESARTAN MEDOXOMIL LITIGATION MCL

In accordance with the provisions of Court Rule 4:38A and Directive #02-19, “Multicounty Litigation Guidelines and Criteria for Designation (Revised),” a previous Notice to the Bar sought comments on the recommendation of Superior Court Judge John C. Porto for conclusion of the Benicar Olmesartan Medoxomil (“Benicar”) litigation MCL. This Notice is to advise that the Supreme Court, after considering the recommendation and having received no comments objecting to the conclusion, has concluded the MCL designation of all pending and future state-court Benicar litigation. The Court’s November 29, 2022 Order is published with this notice.

The notice and order are also posted on the Judiciary’s Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center <https://www.njcourts.gov/attorneys/multicounty-litigation>.

Questions concerning the Court’s conclusion of the MCL designation of the Benicar litigation may be directed to Melissa A. Czartoryski, Esq., Chief, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov.



Glenn A. Grant
Administrative Director of the Courts

Dated: November 29, 2022

SUPREME COURT OF NEW JERSEY

The Supreme Court by Order dated July 14, 2015 designated all New Jersey state court litigation alleging personal injuries arising from treatment with **Benicar Olmesartan Medoxomil** medications as multicounty litigation and assigned that litigation to Atlantic County. The Court's initial Order has since been amended as to the designated judge, including most recently by Order dated April 15, 2019.

It is ORDERED that, effective immediately, the designation of all New Jersey state court Benicar Olmesartan Medoxomil litigation as multicounty litigation is hereby concluded.

For the Court,



Chief Justice

Dated: November 29, 2022